- Home
- CASI vs LRE Comparison
CASI vs LRE Comparison
Compare CASI & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CASI | LRE |
|---|---|---|
| Founded | 1991 | 2001 |
| Country | China | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 20.5M |
| IPO Year | 1996 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CASI | LRE |
|---|---|---|
| Price | $0.94 | $1.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 49.1K | ★ 84.5K |
| Earning Date | 11-14-2025 | 07-30-2015 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.27 |
| EPS | N/A | ★ 0.43 |
| Revenue | $26,846,000.00 | ★ $130,601,512.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.39 |
| Revenue Growth | ★ 21.72 | N/A |
| 52 Week Low | $0.75 | $1.00 |
| 52 Week High | $3.09 | $2.97 |
Technical Indicators
Market Signals| Indicator | CASI | LRE |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 49.70 |
| Support Level | $0.94 | $1.34 |
| Resistance Level | $1.01 | $1.69 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 30.03 | 27.84 |
Price Performance
Historical ComparisonAbout CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.